Literature DB >> 3261155

An IgG subclass imbalance in connective tissue disease.

R A Kay1, K J Wood, R M Bernstein, P J Holt, R S Pumphrey.   

Abstract

A group of 16 patients with a disproportionate polyclonal increase in their serum IgG1, resulting in raised concentrations of total IgG immunoglobulin, has been discovered. The other IgG subclasses in these patients are either normal or slightly reduced, resulting in an IgG1:IgG2 ratio of at least 10:1. Most cases are marked by the presence of anti-extractable nuclear antigen (anti-ENA) antibodies and high titres of rheumatoid factor and antinuclear antibody. All but one patient has a connective tissue disease, nearly twice the prevalence found in similarly hypergammaglobulinaemic patients without this IgG subclass imbalance. Among patients with systemic lupus erythematosus (SLE), those with the IgG1 disorder have a higher prevalence of high titre rheumatoid factor and antinuclear antibody, but a lower prevalence of anti-double-stranded DNA (anti-dsDNA) antibodies above 30 U/ml. It is suggested that this immunoglobulin abnormality may reflect a unique immunoregulatory dysfunction in these patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261155      PMCID: PMC1003566          DOI: 10.1136/ard.47.7.536

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  Secretion of IgG1 induction factor by T cell clones and hybridomas.

Authors:  P Sideras; S Bergstedt-Lindqvist; H R MacDonald; E Severinson
Journal:  Eur J Immunol       Date:  1985-06       Impact factor: 5.532

2.  Is the delayed-type hypersensitivity observed after a low dose of antigen mediated by helper T cells?

Authors:  G Milon; G Marchal; M Seman; P Truffa-Bachi; V Zilberfarb
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

Review 3.  Cellular immune responses in systemic lupus erythematosus.

Authors:  G C Tsokos; J E Balow
Journal:  Prog Allergy       Date:  1984

4.  Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.

Authors:  R M Bernstein; J C Steigerwald; E M Tan
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

5.  Automated filing and reporting in a regional immunology service laboratory using a PET computer.

Authors:  R S Pumphrey
Journal:  Med Inform (Lond)       Date:  1981 Oct-Dec

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Lymphocyte transformation to connective tissue antigens in adult and juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, and a nonarthritic control population.

Authors:  E E Golds; I B Stephen; J M Esdaile; H Strawczynski; A R Poole
Journal:  Cell Immunol       Date:  1983-11       Impact factor: 4.868

8.  Subclass restriction and polyclonality of the systemic lupus erythematosus marker antibody anti-Sm.

Authors:  R A Eisenberg; K Dyer; S Y Craven; C R Fuller; W J Yount
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

9.  In vitro immune response of SLE lymphocytes. The mechanism involved in B-cell activation.

Authors:  T Takeuchi; T Abe; M Kiyotaki; T Toguchi; J Koide; C Morimoto; M Homma
Journal:  Scand J Immunol       Date:  1982-11       Impact factor: 3.487

10.  Human malignant T cells capable of inducing an immunoglobulin class switch.

Authors:  L Mayer; D N Posnett; H G Kunkel
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  9 in total

1.  The "polyclonal hyperimmunoglobulin G1(A1) syndrome" is a secondary phenomenon due to autoimmune disease.

Authors:  M J Krol-van Straaten; H C Haanen; C E de Maat
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

2.  Selective polyclonal increase of immunoglobulin G1 subclass: a link with Sjögren's syndrome.

Authors:  E M Hay; A J Freemont; R A Kay; R M Bernstein; P J Holt; R S Pumphrey
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

3.  Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort.

Authors:  Joo-Hee Kim; Han-Jung Park; Gil-Soon Choi; Jeong-Eun Kim; Young-Min Ye; Dong-Ho Nahm; Hae-Sim Park
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

4.  IgG subclass serum levels in systemic lupus erythematosus patients.

Authors:  Gui-gao Lin; Jin-ming Li
Journal:  Clin Rheumatol       Date:  2009-07-12       Impact factor: 2.980

5.  Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders.

Authors:  S Loizou; C Cofiner; A P Weetman; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

6.  An abnormal T cell repertoire in hypergammaglobulinaemic primary Sjögren's syndrome.

Authors:  R A Kay; E M Hay; P A Dyer; C Dennett; L M Green; R M Bernstein; P J Holt; R S Pumphrey; A W Boylston; W E Ollier
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

7.  Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis.

Authors:  Dolores B Njoku; Jenelle L Mellerson; Monica V Talor; Douglas R Kerr; Nauder R Faraday; Ingrid Outschoorn; Noel R Rose
Journal:  Clin Vaccine Immunol       Date:  2006-02

8.  A Label-Free Immunosensor for IgG Based on an Extended-Gate Type Organic Field Effect Transistor.

Authors:  Tsukuru Minamiki; Tsuyoshi Minami; Ryoji Kurita; Osamu Niwa; Shin-Ichi Wakida; Kenjiro Fukuda; Daisuke Kumaki; Shizuo Tokito
Journal:  Materials (Basel)       Date:  2014-09-22       Impact factor: 3.623

Review 9.  An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.

Authors:  Milla R McLean; Lenette L Lu; Stephen J Kent; Amy W Chung
Journal:  Front Immunol       Date:  2019-12-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.